338 related articles for article (PubMed ID: 37679245)
1. Targeting the adenosine A
Zhao Y; Zhou YG; Chen JF
Chin J Traumatol; 2024 May; 27(3):125-133. PubMed ID: 37679245
[TBL] [Abstract][Full Text] [Related]
2. The belated US FDA approval of the adenosine A
Chen JF; Cunha RA
Purinergic Signal; 2020 Jun; 16(2):167-174. PubMed ID: 32236790
[TBL] [Abstract][Full Text] [Related]
3. Do caffeine and more selective adenosine A
Chen JF; Schwarzschild MA
Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1(Suppl 1):S45-S53. PubMed ID: 33349580
[TBL] [Abstract][Full Text] [Related]
4. Occupancy of adenosine A
Ishibashi K; Miura Y; Wagatsuma K; Toyohara J; Ishiwata K; Ishii K
Neuropharmacology; 2018 Dec; 143():106-112. PubMed ID: 30253174
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotection by caffeine in the MPTP model of parkinson's disease and its dependence on adenosine A2A receptors.
Xu K; Di Luca DG; Orrú M; Xu Y; Chen JF; Schwarzschild MA
Neuroscience; 2016 May; 322():129-37. PubMed ID: 26905951
[TBL] [Abstract][Full Text] [Related]
6. Can adenosine A
Jenner P; Mori A; Kanda T
Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S28-S36. PubMed ID: 33349577
[TBL] [Abstract][Full Text] [Related]
7. Adenosine A
Zhao ZA; Zhao Y; Ning YL; Yang N; Peng Y; Li P; Chen XY; Liu D; Wang H; Chen X; Bai W; Chen JF; Zhou YG
Transl Psychiatry; 2017 May; 7(5):e1123. PubMed ID: 28485728
[TBL] [Abstract][Full Text] [Related]
8. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease.
Kalda A; Yu L; Oztas E; Chen JF
J Neurol Sci; 2006 Oct; 248(1-2):9-15. PubMed ID: 16806272
[TBL] [Abstract][Full Text] [Related]
9. Adenosine A
Nunes ACL; Carmo M; Behrenswerth A; Canas PM; Agostinho P; Cunha RA
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732120
[TBL] [Abstract][Full Text] [Related]
10. A
Lambertucci C; Marucci G; Catarzi D; Colotta V; Francucci B; Spinaci A; Varano F; Volpini R
Curr Med Chem; 2022 Aug; 29(28):4780-4795. PubMed ID: 35184706
[TBL] [Abstract][Full Text] [Related]
11. Time-Dependent Bidirectional Neuroprotection by Adenosine 2A Receptor in Experimental Traumatic Brain Injury.
Velayutham P; Murthy M; Babu KS
World Neurosurg; 2019 May; 125():e743-e753. PubMed ID: 30735877
[TBL] [Abstract][Full Text] [Related]
12. An overview of adenosine A2A receptor antagonists in Parkinson's disease.
Jenner P
Int Rev Neurobiol; 2014; 119():71-86. PubMed ID: 25175961
[TBL] [Abstract][Full Text] [Related]
13. Crystal structure of the adenosine A
Sun B; Bachhawat P; Chu ML; Wood M; Ceska T; Sands ZA; Mercier J; Lebon F; Kobilka TS; Kobilka BK
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):2066-2071. PubMed ID: 28167788
[TBL] [Abstract][Full Text] [Related]
14. Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience.
Hauser RA; Schwarzschild MA
Drugs Aging; 2005; 22(6):471-82. PubMed ID: 15974638
[TBL] [Abstract][Full Text] [Related]
15. Istradefylline: adenosine A2A receptor antagonist to reduce "OFF" time in Parkinson's disease.
Paton DM
Drugs Today (Barc); 2020 Feb; 56(2):125-134. PubMed ID: 32163528
[TBL] [Abstract][Full Text] [Related]
16. A2A Adenosine Receptor Antagonists as Therapeutic Candidates: Are They Still an Interesting Challenge?
Cacciari B; Spalluto G; Federico S
Mini Rev Med Chem; 2018; 18(14):1168-1174. PubMed ID: 29692248
[TBL] [Abstract][Full Text] [Related]
17. Allosteric mechanisms within the adenosine A2A-dopamine D2 receptor heterotetramer.
Ferré S; Bonaventura J; Tomasi D; Navarro G; Moreno E; Cortés A; Lluís C; Casadó V; Volkow ND
Neuropharmacology; 2016 May; 104():154-60. PubMed ID: 26051403
[TBL] [Abstract][Full Text] [Related]
18. Adenosine A
Franco R; Rivas-Santisteban R; Casanovas M; Lillo A; Saura CA; Navarro G
Cells; 2020 Apr; 9(5):. PubMed ID: 32357548
[TBL] [Abstract][Full Text] [Related]
19. Istradefylline - a first generation adenosine A
Jenner P; Mori A; Aradi SD; Hauser RA
Expert Rev Neurother; 2021 Mar; 21(3):317-333. PubMed ID: 33507105
[No Abstract] [Full Text] [Related]
20. Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists.
Szabó N; Kincses ZT; Vécsei L
Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):441-55. PubMed ID: 21332415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
